Skip to main content
BBIO
NASDAQ Life Sciences

BridgeBio Submits NDA to FDA for Encaleret, a Potential First-in-Class Therapy for ADH1

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$68.61
Mkt Cap
$13.438B
52W Low
$31.77
52W High
$84.94
52W Position info
116% above low
Off High info
19% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

BBIO has more than doubled off its 52-week low of $31.77.

Summary

BridgeBio Pharma submitted a New Drug Application (NDA) to the FDA for encaleret, a potential first-in-class treatment for autosomal dominant hypocalcemia type 1 (ADH1), following successful Phase 3 clinical trials.


Key Events · Product Development and Regulatory · BBIO

  • NDA Submitted for Encaleret

    BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, an investigational therapy for autosomal dominant hypocalcemia type 1 (ADH1).

  • Successful Phase 3 CALIBRATE Trial

    The Phase 3 CALIBRATE trial met all pre-specified primary and key secondary efficacy endpoints, demonstrating rapid and durable benefits in mineral homeostasis for ADH1 patients.

  • Potential First-in-Class Therapy

    Encaleret, if approved, could be the first approved therapy specifically indicated for individuals living with ADH1, addressing the underlying genetic cause of the disease.

  • Anticipated Early 2027 U.S. Launch

    BridgeBio anticipates a U.S. launch for encaleret in early 2027, with potential eligibility for priority review by the FDA.


Analysis · BBIO · Life Sciences

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, a significant step towards commercialization for autosomal dominant hypocalcemia type 1 (ADH1). This submission follows highly positive Phase 3 CALIBRATE trial results, where encaleret demonstrated rapid and durable benefits, meeting all primary and key secondary efficacy endpoints. If approved, encaleret would be the first targeted therapy for ADH1, addressing the underlying genetic cause and potentially launching in early 2027. This milestone significantly de-risks a key pipeline asset and expands the company's potential market opportunity, with plans to also initiate a Phase 3 study for chronic hypoparathyroidism.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBIO was trading at $68.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4B. The 52-week trading range was $31.77 to $84.94. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $74.36 info
Change: +$3.67 (+5%) info
Market Cap: $14.472B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $74.36 info
Change: +$2.92 (+4%) info
Market Cap: $14.472B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $74.36 info
Change: +$3.69 (+5%) info
Market Cap: $14.472B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $74.36 info
Change: +$8.61 (+13%) info
Market Cap: $14.472B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $74.36 info
Change: +$9.01 (+14%) info
Market Cap: $14.472B info